ABL1 T315I Recombinant Human Active Protein Kinase
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) . ABL1 T315I Recombinant Human Active Protein Kinase is a recombinant ABL1 T315I protein that can be used to study ABL1 T315I-related functions[1].
Product Specifications
UNSPSC
12352211
Target
Bcr-Abl
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
[ABL1T315IRecombinantHumanActiveProteinKinase]
References & Citations
[1]Yusoff YM, et al. Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance. Malays J Pathol. 2024 Dec;46 (3) :431-439.
Shipping Conditions
Room temperature
Scientific Category
Enzyme
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
044531-01 50 µg
ANGPTL4, coiled-coil domain (Angiopoietin-like Protein 4, FIAF, Fasting-induced Adipose Factor, HFARP, Hepatic Fibrinogen/Angiopoietin-related Protein)
Ask
View Details 044531-02 100 µg
ANGPTL4, coiled-coil domain (Angiopoietin-like Protein 4, FIAF, Fasting-induced Adipose Factor, HFARP, Hepatic Fibrinogen/Angiopoietin-related Protein)
Ask
View Details